At CALIXAR, we are providing access to our toolbox engine, to any partner who wanted to contribute to generate drugs, antibodies or vaccines of such challenging virus.
We previously reported the use of novel approaches to enable low dose split inactivated vaccine protection against influenza infection (Mandon E et al., Vaccine, 2020). Great results were also obtained for the discovery of new treatments against other challenging enveloped viruses such as Arbovirus and good progress on HIV as well (Jawhari A et al., World Vaccine Congress, Washington 2017).
In addition to vaccine development, our technological platform has delivered an outstanding track record on broad range of membrane protein families and antigens to enable small molecules discovery as well as antibody development. We are convinced that such experience and technological platform can support the drug and vaccine discoveries and further treat patient with covid-19.
About Covid-19 Virtual Partnering:
To support the fight against Covid-19 Lyonbiopole, Evaluate Ltd. and Inova are organizing a free Virtual Partnering Event to connect organizations with solutions for Covid-19. Many pharmaceutical industries will be present. The objective is to gather all knowledge and technologies that can help in the effort to develop prevention solutions to tackle the Covid-19 pandemic.
For more information and contribute together to stopping outbreak of Coronavirus: https://virtual-partnering.com/